Expression and clinical significance of lymphocyte function-associated antigen 3 (LFA-3) in low-grade glioma

VernacularTitle:淋巴细胞功能相关抗原3在低分级胶质瘤中的表达及临床意义
Author: Hao ZHAO ; Hulin ZHAO ; Hailong LI ; Chunhui ZHOU ; Jianning ZHANG
Keywords: gliomas; lymphocyte function-associated antigen 3; therapeutic target
From: Chinese Journal of Clinical Oncology 2017;44(15):755-759
CountryChina
Language:Chinese
Abstract: Objective:To explore the relationship of lymphocyte function-associated antigen 3 (LFA-3, CD58) expression in glioma with clinical features and its role in clinical prognosis. Methods:Clinical data and mRNA microarray data of 514 patients with glioma were obtained from The Cancer Genome Atlas and were used to study the expression of LFA-3 (CD58). Cox regression was used to analyze the relationship between CD58 expression and survival of patients with glioma. Multivariate analysis of variance was used to further analyze the relationship of CD58 with age, sex, and pathological grade of glioma. Results:The results of the stratified χ2 test of CD58 expression and tumor grading were shown, considering tumor type, gender and age of diagnosis (all P<0.05). CD58 expression was sig-nificantly correlated with overall survival (OS) and disease-free survival (DFS) of patients with glioma. Patients with high CD58 expres-sion presented short OS and DFS (P<0.0001). Conclusion:CD58 possibly promotes tumorigenesis in gliomas and thus can serve as a potential tumor diagnostic marker and individual therapeutic target.